The key players in the paroxysmal nocturnal hemoglobinuria (PNH) treatment market include Alexion Pharmaceuticals, Inc., Akari Therapeutics, Plc, Apellis Pharmaceuticals, Inc., Amgen, Inc., Alnylam Pharmaceuticals, Inc., CinnaGen Co., Plc, Ra Pharmaceuticals, Inc.
The rise in a number of blood and bone marrow related disorders and increase in geriatric population are the key factors which drive the market growth of PNH treatment market. In addition to this, the emergence of biologics and adoption of novel therapeutics are further pushing the market growth. However, adverse effects associated with currently available treatments, increase in the cost of medical equipment, specifically surgical equipment required for stem cell transformation are some factors that restrain market growth of PNH.
The broad paroxysmal nocturnal hemoglobinuria (PNH) treatment market has been sub-grouped into treatment. current and forecast demand for paroxysmal nocturnal hemoglobinuria (PNH) treatment in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
By Treatment
- Medication
- Stem Cell Transplant
- Blood Transfusion
Source: https://www.valuemarketresearch.com/report/paroxysmal-nocturnal-hemoglobinuria-pnh-treatment-market
Naira Shekhawat has been into Content Writing just after completing her Graduation in English Literature. Her love for words has won her many accolades in her respective jobs ever since. Naira covers business sections for VMR News. She is a traveller by heart and loves writing on food blogs as a freelancer.